The global exosomes market size is expected to reach USD 2.28 billion by 2030, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 18.8% during the forecast period. Nanovesicles, which play a major role in intercellular communication, are anticipated to witness a significant rise in R&D, thus leading to revenue growth in the coming years.
Application of these vesicles as carriers of functional content such as circulating nucleic acids, lipids, and proteins can be attributed to market growth. In addition, exosomes play an important role in immunosurveillance and tumor pathogenesis. Increasing research programs focusing on determining the role of exosomes in hepatocellular carcinoma (HCC) is estimated to drive the market.
The rising number of articles pertaining to exosomal research is encouraging R&D activities in the field. Currently, there are more than 4400 articles published about exosomes, with approximately 25% of these published in 2016 alone. In addition to the exponential rise in article publication, the number of companies engaged in the research is also increasing.
These companies are taking advantage of the natural propensity of exosomes for the transmission of macromolecule payloads between cells. The application of these molecules in research activities related to therapeutics and diagnostics is projected to result in exponential growth in the coming years.
Moreover, an increase in funding for R&D in this field is poised to positively influence industrial growth. Rise in funding capacity by public and private institutions is indicative of the importance of exRNA molecules across the community engaged in translational research pertaining to diagnostics and therapeutic product development.
To request a sample copy or view summary of this report, click the link below:
Further key findings from the report suggest:
By workflow, the downstream analysis will account for a little over half the market revenue in 2030, due to rising advancements in methods and instruments
Ultracentrifugation represented the leading share in the isolation methods segment owing to the higher adoption of technology as compared to other methods of isolation. Immunocapture on beads is anticipated to witness the fastest growth over the forecast period due to advancements in lab-on-a-chip techniques
In 2016, cancer was the leading application segment with a valuation of USD 1.15 million. Increasing penetration of companies in oncology-based research on biomarker identification is contributing to the growth of the segment
North America commanded the dominant share in terms of market revenue due to the presence of a large number of academic and private organizations engaged in the launch of novel technologies
Major participants operating in this sector include Takara Bio Company; Illumina, Inc.; Thermo Fisher Scientific, Inc.; Fujifilm; and Qiagen. Strategies adopted by these participants include patent filing, the inauguration of certified production facility, and the launch of novel instruments.
Grand View Research has segmented the global exosomes market on the basis of workflow, biomolecule type, application, and region:
Exosomes Workflow Outlook (Revenue, USD Million, 2014 - 2030)
Immunocapture on beads
Cell Surface Marker Analysis using Flow Cytometry
Protein analysis using Blotting & ELISA
RNA analysis with NGS & PCR
Proteomic analysis using Mass Spectrometry
Exosomes Biomolecule Type Outlook (Revenue, USD Million, 2014 - 2030)
Exosomes Application Outlook (Revenue, USD Million, 2014 - 2030)
Exosomes Regional Outlook (Revenue, USD Million, 2014 - 2030)
The Middle East and Africa (MEA)
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."